{"count": 3, "results": [{"_id": "35061024", "pmid": 35061024, "title": "Islet Autoimmunity is Highly Prevalent and Associated With Diminished beta-Cell Function in Patients With Type 2 Diabetes in the Grade Study.", "journal": "Diabetes", "authors": ["Brooks-Worrell B", "Hampe CS", "Hattery EG", "Palomino B", "Zangeneh SZ", "Utzschneider K", "Kahn SE", "Larkin ME", "Johnson ML", "Mather KJ", "Younes N", "Rasouli N", "Desouza C", "Cohen RM", "Park JY", "Florez HJ", "Valencia WM", "GRADE Beta-cell Ancillary Study Network", "Shojaie A", "Palmer JP", "Balasubramanyam A"], "date": "2022-01-21T00:00:00Z", "doi": "10.2337/db21-0590", "meta_date_publication": "2022 Jan 21", "meta_volume": "71", "meta_issue": "6", "meta_pages": "1261-71", "score": 50250.832, "text_hl": "In this ancillary study to the Glycemia Reduction Approaches in @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@Diabetes@@@-A Comparative Effectiveness (GRADE) Study, we investigated the prevalence of cellular and humoral @<m>DISEASE_Adenoma_Islet_Cell</m> @DISEASE_MESH:D007516 @@@islet autoimmunity@@@ in @SPECIES_9606 @@@patients@@@ with @DISEASE_Diabetes_Mellitus_Type_2 @DISEASE_MESH:D003924 @@@T2D@@@ duration 4 0+-3 0 y, HbA1c 7 5+-0 5% on @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ alone. ", "citations": {"NLM": "Brooks-Worrell B, Hampe CS, Hattery EG, Palomino B, Zangeneh SZ, Utzschneider K, Kahn SE, Larkin ME, Johnson ML, Mather KJ, Younes N, Rasouli N, Desouza C, Cohen RM, Park JY, Florez HJ, Valencia WM, GRADE Beta-cell Ancillary Study Network, Shojaie A, Palmer JP, Balasubramanyam A. Islet Autoimmunity is Highly Prevalent and Associated With Diminished beta-Cell Function in Patients With Type 2 Diabetes in the Grade Study. Diabetes. 2022 Jan 21;71(6):1261-71. PMID: 35061024", "BibTeX": "@article{35061024, title={Islet Autoimmunity is Highly Prevalent and Associated With Diminished beta-Cell Function in Patients With Type 2 Diabetes in the Grade Study.}, author={Brooks-Worrell B and Hampe CS and Hattery EG and Palomino B and Zangeneh SZ and Utzschneider K and Kahn SE and Larkin ME and Johnson ML and Mather KJ and Younes N and Rasouli N and Desouza C and Cohen RM and Park JY and Florez HJ and Valencia WM and GRADE Beta-cell Ancillary Study Network and Shojaie A and Palmer JP and Balasubramanyam A}, journal={Diabetes}, volume={71}, number={6}, pages={1261-71}}"}}, {"_id": "15983227", "pmid": 15983227, "title": "Long-term treatment with rosiglitazone and metformin reduces the extent of, but does not prevent, islet amyloid deposition in mice expressing the gene for human islet amyloid polypeptide.", "journal": "Diabetes", "authors": ["Hull RL", "Shen ZP", "Watts MR", "Kodama K", "Carr DB", "Utzschneider KM", "Zraika S", "Wang F", "Kahn SE"], "date": "2005-07-01T00:00:00Z", "doi": "10.2337/diabetes.54.7.2235", "meta_date_publication": "2005 Jul", "meta_volume": "54", "meta_issue": "7", "meta_pages": "2235-44", "score": 50060.555, "text_hl": "Human IAPP (hIAPP) transgenic @SPECIES_10090 @@@mice@@@, a model of @<m>DISEASE_Adenoma_Islet_Cell</m> @DISEASE_MESH:D007516 @@@islet amyloid@@@, were treated for 12 months with @CHEMICAL_Rosiglitazone @CHEMICAL_MESH:D000077154 @@@rosiglitazone@@@ (1.5 mg.kg(-1).day(-1), n = 19), @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ (1 g.kg(-1).day(-1), n = 18), or control (n = 17). ", "citations": {"NLM": "Hull RL, Shen ZP, Watts MR, Kodama K, Carr DB, Utzschneider KM, Zraika S, Wang F, Kahn SE. Long-term treatment with rosiglitazone and metformin reduces the extent of, but does not prevent, islet amyloid deposition in mice expressing the gene for human islet amyloid polypeptide. Diabetes. 2005 Jul;54(7):2235-44. PMID: 15983227", "BibTeX": "@article{15983227, title={Long-term treatment with rosiglitazone and metformin reduces the extent of, but does not prevent, islet amyloid deposition in mice expressing the gene for human islet amyloid polypeptide.}, author={Hull RL and Shen ZP and Watts MR and Kodama K and Carr DB and Utzschneider KM and Zraika S and Wang F and Kahn SE}, journal={Diabetes}, volume={54}, number={7}, pages={2235-44}}"}}, {"_id": "23184570", "pmid": 23184570, "title": "Linagliptin/Metformin fixed-dose combination treatment: a dual attack to type 2 diabetes pathophysiology.", "journal": "Adv Ther", "authors": ["Koliaki C", "Doupis J"], "date": "2012-12-01T00:00:00Z", "doi": "10.1007/s12325-012-0067-z", "meta_date_publication": "2012 Dec", "meta_volume": "29", "meta_issue": "12", "meta_pages": "993-1004", "score": 50048.887, "text_hl": "As a result, a @CHEMICAL_Linagliptin @CHEMICAL_MESH:D000069476 @@@linagliptin@@@/@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ fixed-dose combination offers the potential to address multiple defects of @DISEASE_Diabetes_Mellitus_Type_2 @DISEASE_MESH:D003924 @@@type 2 diabetes@@@ pathophysiology (@<m>DISEASE_Adenoma_Islet_Cell</m> @DISEASE_MESH:D007516 @@@pancreatic islet dysfunction@@@, @DISEASE_Insulin_Resistance @DISEASE_MESH:D007333 @@@insulin resistance@@@, increased hepatic @CHEMICAL_Glucose @CHEMICAL_MESH:D005947 @@@glucose@@@ output), and most importantly, in the context of a safe, efficacious, flexible, and convenient therapeutic regimen.", "citations": {"NLM": "Koliaki C, Doupis J. Linagliptin/Metformin fixed-dose combination treatment: a dual attack to type 2 diabetes pathophysiology. Adv Ther. 2012 Dec;29(12):993-1004. PMID: 23184570", "BibTeX": "@article{23184570, title={Linagliptin/Metformin fixed-dose combination treatment: a dual attack to type 2 diabetes pathophysiology.}, author={Koliaki C and Doupis J}, journal={Adv Ther}, volume={29}, number={12}, pages={993-1004}}"}}]}